Lifeboat Foundation

Antibiotic resistance is a global human health threat, causing routine treatments of bacterial infections to become increasingly difficult. The problem is exacerbated by biofilm formation by bacterial pathogens on the surfaces of indwelling medical and dental devices that facilitate high levels of tolerance to antibiotics. The development of new antibacterial nanostructured surfaces shows excellent prospects for application in medicine as next-generation biomaterials. The physico-mechanical interactions between these nanostructured surfaces and bacteria lead to bacterial killing or prevention of bacterial attachment and subsequent biofilm formation, and thus are promising in circumventing bacterial infections. This Review explores the impact of surface roughness on the nanoscale in preventing bacterial colonization of synthetic materials and categorizes the different mechanisms by which various surface nanopatterns exert the necessary physico-mechanical forces on the bacterial cell membrane that will ultimately result in cell death.

In a recent study conducted in mice, researchers became one step closer to that understanding, discovering that exercise actually strengthens the brain’s resilience to stress. Exercise helps animals cope with stress by enabling an uptick in a crucial neural protein called galanin, the study suggests. This process influences stress levels, food consumption, cognition, and mood.

Leveraging this finding, researchers were able to genetically tweak even sedentary mice’s levels of galanin, shifts that lowered their anxious response to stress.

The study’s authors explain that this study helps pin down the biological mechanisms driving exercise’s positive effects on stress. While further human experiments are needed to confirm these findings, the researchers have practical advice for people looking to get these benefits: perform regular, aerobic exercise.

MILLIONS MORE are going to die before the covid-19 pandemic is over. That is the stark message of Bill Gates, a co-founder of Microsoft and one of the world’s largest philanthropists via the Bill & Melinda Gates Foundation, in an interview with Zanny Minton Beddoes, The Economist’s editor-in-chief, in early August. Most of these deaths, he said, would be caused not by the disease itself, but by the further strain on health-care systems and economies that were already struggling.

But he offered reasons for hope in the medium term, predicting that by the end of 2021 a reasonably effective vaccine would be in mass production, and a large enough share of the world’s population would be immunised to halt the pandemic in its tracks.

Continue reading “The covid-19 pandemic will be over by the end of 2021, says Bill Gates” »

Sarcos Robotics, a startup developing robots for industrial and defense applications, today nabbed $40 million in equity financing, bringing its total venture capital raised to nearly $100 million. The company plans to use the capital to commercialize its first full-body, self-powered product — the Guardian XO — ahead of an anticipated 2021 ship date.

According to a 2020 Grand View Research report, the exoskeleton market could be worth $4.2 billion by 2027. The firm sees adoption growing steeply in health care, where exoskeletons could address the increased prevalence of spinal cord injuries in industries like security, disaster recovery, infrastructure inspection and maintenance, maritime, oil and gas, and mining. The National SCI Statistical Center reported 17,730 new spinal cord injuries in 2019 in the U.S. alone.

Sarcos spun out from the University of Utah in 1983 and for years operated as a bioengineering research institution. By 2000, the lab had expanded into segments like animated film props, prostheses, and human-computer interfaces. A DARPA grant to develop a military exoskeleton steered Sarcos toward defense applications. After DARPA accepted Sarcos’ proposal in 2006, the company began developing prototypes and contracted with the U.S. Navy to pilot salvage robots.

Amazon Prime Air has cleared a regulatory hurdle, moving the online retail giant one step closer to dropping packages off at your doorstep with drones. The US Federal Aviation Administration on Saturday issued Amazon Prime Air a “a Part 135 air carrier certificate,” allowing it to begin commercial drone deliveries in the US.

“Amazon Prime Air’s concept uses autonomous [unmanned aircraft systems] to safely and efficiently deliver packages to customers,” said a spokesperson for the FAA on Monday. “The FAA supports innovation that is beneficial to the public, especially during a health or weather-related crisis.”

Amazon and other companies are trying to make drones the future of deliveries.

The news: IBM has built a new chemistry lab called RoboRXN in the cloud. It combines AI models, a cloud computing platform, and robots to help scientists design and synthesize new molecules while working from home.

How it works: The online lab platform allows scientists to log on through a web browser. On a blank canvas, they draw the skeletal structure of the molecular compounds they want to make, and the platform uses machine learning to predict the ingredients required and the order in which they should be mixed. It then sends the instructions to a robot in a remote lab to execute. Once the experiment is done, the platform sends a report to the scientists with the results.

Why it matters: New drugs and materials traditionally require an average of 10 years and $10 million to discover and bring to market. Much of that time is taken up by the laborious repetition of experiments to synthesize new compounds and learn from trial and error. IBM hopes that a platform like RoboRXN could dramatically speed up that process by predicting the recipes for compounds and automating experiments. In theory, it would lower the costs of drug development and allow scientists to react faster to health crises like the current pandemic, in which social distancing requirements have caused slowdowns in lab work.

The coronavirus disease 2019 (COVID-19) pandemic has had a global impact on all aspects of health care, including surgical procedures. For urologists, it has affected and will continue to influence how we approach the care of patients preoperatively, intraoperatively, and postoperatively. A risk-benefit assessment of each patient undergoing surgery should be performed during the COVID-19 pandemic based on the urgency of the surgery and the risk of viral illness and transmission. Patients with advanced age and comorbidities have a higher incidence of mortality. Routine preoperative testing and symptom screening is recommended to identify those with COVID-19. Adequate personal protective equipment (PPE) for the surgical team is essential to protect health care workers and ensure an adequate workforce. For COVID-19 positive or suspected patients, the use of N95 respirators is recommended if available. The anesthesia method chosen should attempt to minimize aerosolization of the virus. Negative pressure rooms are strongly preferred for intubation/extubation and other aerosolizing procedures for COVID-19 positive patients or when COVID status is unknown. Although transmission has not yet been shown during laparoscopic and robotic procedures, efforts should be made to minimize the risk of aerosolization. Ultra-low particulate air filters are recommended for use during minimally invasive procedures to decrease the risk of viral transmission. Thorough cleaning and sterilization should be performed postoperatively with adequate time allowed for the operating room air to be cycled after procedures. COVID-19 patients should be separated from noninfected patients at all levels of care, including recovery, to decrease the risk of infection. Future directions will be guided by outcomes and infection rates as social distancing guidelines are relaxed and more surgical procedures are reintroduced. Recommendations should be adapted to the local environment and will continue to evolve as more data become available, the shortage of testing and PPE is resolved, and a vaccine and therapeutics for COVID-19 are developed.

The first reported cases of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan City, Hubei Province, China in December 2019. This respiratory disease spread outside of China, leading to outbreaks in Korea, Iran, Italy, and, eventually, the United States and the rest of the world. On March 11, 2020, the World Health Organization (WHO) declared the outbreak to be a pandemic. At the time of this writing, there are currently more than 1.3 million confirmed cases worldwide, with the total deaths numbering more than 74,000.¹ This pandemic is unlike anything that has been seen in recent history.

From a urologic surgery perspective, many questions arise regarding the immediate and long-term care of our patients. The goal of this article is to summarize some of the current information available on preoperative, intraoperative, and postoperative care. As we gain more knowledge about how the virus behaves, this body of literature will inevitably change.

Chilled panels use less energy than conventional A/C and work in open spaces.

Many people beat the summer heat by cranking the air conditioning. However, air conditioners guzzle power and spew out millions of tons of carbon dioxide daily. They’re also not always good for your health—constant exposure to central A/C can increase risks of recirculating germs and causing breathing problems.

There’s a better alternative, say a team of researchers from the University of British Columbia, Princeton University, the University of California, Berkeley and the Singapore-ETH Centre.

In just two years a robotic device that prints a patient’s own skin cells directly onto a burn or wound could have its first-in-human clinical trials. The 3D bioprinting system for intraoperative skin regeneration developed by Australian biotech start-up Inventia Life Science has gained new momentum thanks to major investments from the Australian government and two powerful new partners, world-renowned burns expert Fiona Wood and leading bioprinting researcher Gordon Wallace.

Codenamed Ligō from the Latin “to bind”, the system is expected to revolutionize wound repairs by delivering multiple cell types and biomaterials rapidly and precisely, creating a new layer of skin where it has been damaged. The novel system is slated to replace current wound healing methods that simply attempt to repair the skin, and is being developed by Inventia Skin, a subsidiary of Inventia Life Science.

“When we started Inventia Life Science, our vision was to create a technology platform with the potential to bring enormous benefit to human health. We are pleased to see how fast that vision is progressing alongside our fantastic collaborators. This Federal Government support will definitely help us accelerate even faster,” said Dr. Julio Ribeiro, CEO, and co-founder of Inventia.